Search
Octreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalAcromegaly is a life-threatening disease requiring life-long management. … [L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsProducts: SANDOSTATİN 0,1 MG/ML SC/IV ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİGadoquatrane
go.drugbank.com/drugs/DB33282ApprovedGadoquatrane is a macrocyclic gadolinium-based contrast agent used to enhance magnetic resonance imaging. … [L63814] Like other gadolinium agents it is paramagnetic, developing a magnetic moment in the scanner's field that alters the relaxation of nearby water protons and brightens tissues with abnormal vascularity
AMY-101
go.drugbank.com/drugs/DB14803InvestigationalAMY-101, also known as compstatin 40, is a peptidic inhibitor of the central complement component C3. … AMY-101 is under investigation in clinical trial NCT03694444 (A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis).
AAV1-FS344
go.drugbank.com/drugs/DB17855InvestigationalAAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.
Tezosentan
go.drugbank.com/drugs/DB06558InvestigationalTezosentan is an intravenous endothelin receptor A/B antagonist.
Plitidepsin
go.drugbank.com/drugs/DB04977InvestigationalAplidine is also of interest as a potential treatment for some leukemias. … Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is _Aplidium albicans_.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesOTL-201
go.drugbank.com/drugs/DB17652ExperimentalIt consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973] … OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA).
Androstenediol
go.drugbank.com/drugs/DB01524ExperimentalIllicitAndrostenediol is an intermediate in [testosterone] biosynthesis, found in the testis or the adrenal glands. … Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group to a
TD-2749
go.drugbank.com/drugs/DB05905Experimentalsuch as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis. … TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders
OBE101
go.drugbank.com/drugs/DB05080ExperimentalOBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.